World Clinical Trials Day (May 20) offers a timely opportunity to highlight the strategic importance of clinical research—for patients, the healthcare system, and the national economy—amid growing global challenges and intensifying international competition to attract investment.
A Competitive Global Landscape
Clinical trials today operate in an increasingly competitive international arena. Greece continues to underperform relative to its potential in this field, with investment levels remaining stagnant—and below what would be expected for a country of its size.
Clear, Multilayered Benefits
Yet the advantages for healthcare, patients, and the broader economy are well documented and wide-ranging: improved access to innovation, cost savings for the health system, and strengthened scientific capacity. Specifically, clinical trials:
- Give patients early access to cutting-edge therapies—often years before market approval;
- Provide vital financial and scientific support to public hospitals and researchers;
- Help retain highly specialized healthcare professionals in Greece;
- Generate significant resource savings for the health system by offering expensive treatments and diagnostic or laboratory tests free of charge within trial protocols.
For example, a modern cancer immunotherapy may cost around €70,000—yet neither patients nor the public health system bear that cost when delivered through a clinical trial.
A Strategic Priority for Greece
Attracting clinical trials must become a national strategic priority. Equally important is sending a clear signal that Greece recognizes and supports pharmaceutical innovation. With targeted reforms, the country can recover lost ground and evolve into a regional hub for clinical research.
Key Challenges to Address
The current state of research activity in Greece points to four critical areas needing improvement:
- Better patient selection processes for trial participation;
- Specialized training for hospital administrative and financial staff;
- Simplification of regulatory frameworks and procedural requirements;
- Implementation of meaningful incentives for Research & Development investment—and digitalization of supporting infrastructure.
What needs to be done is no longer in question. The critical question now is: Does the state have the political will to act?